ĐẠI HỌC QUỐC GIA HÀ NỘI TRƯỜNG ĐẠI HỌC KHOA HỌC TỰ NHIÊN TRẦN THỊ YẾN NGHIÊN CỨU QUI TRÌNH TỔNG HỢP LIÊN TỤC VÀ TINH CHẾ CELECOXIB LUẬN VĂN THẠC SĨ KHOA HỌC... ĐẠI HỌC QUỐC GIA HÀ NỘ
Trang 1ĐẠI HỌC QUỐC GIA HÀ NỘI TRƯỜNG ĐẠI HỌC KHOA HỌC TỰ NHIÊN
TRẦN THỊ YẾN
NGHIÊN CỨU QUI TRÌNH TỔNG HỢP LIÊN TỤC VÀ TINH CHẾ
CELECOXIB
LUẬN VĂN THẠC SĨ KHOA HỌC
Trang 2ĐẠI HỌC QUỐC GIA HÀ NỘI TRƯỜNG ĐẠI HỌC KHOA HỌC TỰ NHIÊN
TRẦN THỊ YẾN
NGHIÊN CỨU QUI TRÌNH TỔNG HỢP LIÊN TỤC VÀ TINH CHẾ
CELECOXIB
Chuyên nghành: Hóa hữu cơ
Mã số: 60440114
LUẬN VĂN THẠC SĨ KHOA HỌC
Người hướng dẫn khoa học: TS Ngô Quốc Anh
Hà Nội - 2016
Trang 3TÀI LIỆU THAM KHẢO
A Tiếng Việt
1 Đào Văn Phan (2007), Dược lý học, tập 1, Nhà xuất bản Giáo dục, Hà Nội
2 Mai Tất Tố (2007), Dược lý học, tập 2, Nhà xuất bản Y học, Hà Nội
3 (2010), Vidal Việt Nam, Nhà xuất bản CMPMedica Asia Pte Ltd, Tp Hồ Chí
Minh
B Tiếng Anh
4 Anumula, et al (2008), Process for preparation of celecoxib, US patent, US
20080234491A1
5 Beuck M (1999), "Nonsteroidal antiinflammatory drugs: A new generation
of cyclooxygenase inhibitors", Angew Chem Int Ed., 38, pp 0631-0633
6 Coruzzi G., Venturi N., Spaggiari S (2007), " Gastrointestinal safety of
novel nonsteroidal antiinflammatory drugs: Selective cox-2 inhibitors
and beyond", Acta Biomed, 78, pp 96-110
7 Davies N M., et al (2000), "Clinical pharmacokinetics and pharmacodynamics
of celecoxib: A selective cyclo-oxygenase-2 inhibitor", Clin Pharmacokinet,
38(3), pp 225-242
8 Farooq M., et al (2008), " Cardiovascular risks of cox inhibition: Current
perspectives", A.S.Expert Opin Pharmacother, 9, pp 1311-1319
9 Ferro, et al (2004), Polymorphic crystalline forms of celecoxib, United
States Patent, US 20040087640A1(5/2004)
Trang 410 Frampton J E., Keating G M (2007), "Celecoxib: A review of its use in the
management of arthritis and acute pain", Drugs, 67(16), pp 2433-2472
11 Furniss B S., et al (1989), "Vogel's textbook of practical organic
chemistry", Longman Scientific & technical, 5th edition, pp 959
12 Gandey A (2011), "All nonsteroidal anti-inflammatory drugs have
cardiovascular ricks", BMJ
13 Harris R E., et al (2000), "Chemoprevention of breast cancer in rats by
celecoxib, a cyclooxygenase 2 inhibitor", Cancer Res, 60(8), pp 2101-2103
14 Jeffery S C (2000), "Inhibitors of cyclooxygenase-2", Exp Opin Ther
Patents, 10(7), pp 1011-1020
15 Jones R., et al ( 2008), "Gastrointestinal and cardiovascular risks of
nonsteroidal antiinflammatory drugs", Am J Med., 121, pp 464-474
16 Kalgutkar A S , Lawrence J M (1998), "Design of selective inhibitors of
cyclooxygenase-2 as nonulcerogenic anti-inflammatory agents", Current
Opinion in Chemical Biology, 2, pp 482-490
17 Letendre, et al (2007), "Synthesis of diaryl pyrazoles", US patent, US
20070004924A1(1/2007)
18 Li J J , et al (2004), "Anti-inflammatory cyclooxygenase-2 selective
inhibitors: Celecoxib (celebrex) and rofecoxib (vioxx)", Contemporary Drug
Synthesis, pp 11-19
19 Loewen P S (2002), "Review of the selective cox-2 inhibitors celecoxib and
rofecoxib: Focus on clinical aspects", CJEM, 4(4), pp 268-275
Trang 520 Lynette M O (2006), "Synthesis of celecoxib via 1,3-dipolar cycloaddition",
ScienceDirect, 47(45), pp 7943-7946
21 Masferrer J L., et al (2000), "Antiangiogenic and antitumor activities of
cyclooxygenase-2 inhibitors", Cancer Res, 60(5), pp 1306-1311
22 Micheal B S , Jerry March (2001), "March's advanced organic chemistry:
Reactions, mechanisms and structure", Wiley - Interscience, 5th edition, pp
1556
23 Moore R A., et al (2005), "Tolerability and adverse events in clinical trials of
celecoxib in osteoarthritis and rheumatoid arthritis: Systematic review and
meta-analysis of information from company clinical trial reports", Arthritis
Res Ther, 7(3), pp R644-665
24 O'Shea, et al (2001), Synthesis of 4-[(5-substituted
phenyl)-3-substituted-lh-pyrazol-l-yljbenzenesulfonamide, United States Patent, S006232472B1
(5/2001)
25 Penning T D., et al (1997), "Synthesis and biological evaluation of the
1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl]benze nesulfonamide
(sc-58635, celecoxib)", J Med Chem, 40(9), pp 1347-1365
26 Reddy B S., et al (2000), "Chemoprevention of colon cancer by specific
cyclooxygenase-2 inhibitor, celecoxib, administered during different stages
of carcinogenesis", Cancer Res, 60(2), pp 293-297
27 Reddy M., et al (2003), Process for the preparation of 1,5-diarylpyraroles,
World Intellectual Property Organization, WO 03/024400 A2.(3/2003)
28 Sanghi S., et al (2006), "Cyclooxygenase-2 inhibitors: A painful lesson",
Cardiovasc Hematol Disord Drug Targets, 6(2), pp 85-100
Trang 629 Silverstein F E., et al (2000), "Gastrointestinal toxicity with celecoxib vs
nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The class study: A randomized controlled trial Celecoxib long-term
arthritis safety study", JAMA, 284(10), pp 1247-1255
30 Simon L S., et al (1999), "Anti-inflammatory and upper gastrointestinal
effects of celecoxib in rheumatoid arthritis: A randomized controlled trial",
JAMA, 282(20), pp 1921-1928
31 Talley J J., et al (2003), Substituted pyrazolyl benzenesulfonamides for the
treatment of inflammation, US patent, 6,586,603,B1(6/2003)
32 Vane J ( 1994), "Towards a better aspirin ", Nature, 367, pp 215-216
33 Zhuang, et al (2004), Stable amorphous celecoxib composite and process
therefor, Patent Application Publication, US 20040030151A1(2/2004)
34 Zhi B., Estates H.; Newaz M., PalatineIll.( 1999), U.S Pat Nos 5,910,597